Novo Nordisk is ramping up the manufacturing capacity of its obesity-related drugs as demand for Wegovy and Ozempic continues to surge. It's pouring $4.1 billion to expand its facility.

Novo Nordisk, the Danish drug maker of the wildly successful obesity drugs, Wegovy and Ozempic, said it plans to invest $4.1 billion for a new plant in the United States to increase the ...

COPENHAGEN/LONDON June 24 - Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and diabetes ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.

(Reuters) -As Denmark's Novo Nordisk shops for its next CEO ... THE U.S. MARKET Trump, who campaigned on a promise to boost domestic manufacturing, has been piling pressure on drugmakers since ...

Novo Nordisk is ramping up the manufacturing capacity of its obesity-related drugs as demand for Wegovy and Ozempic continues to surge. It's pouring $4.1 billion to expand its facility.

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.

which owns 77% of the voting shares in Novo Nordisk. The deal could boost availability of the drugs because Catalent is the main supplier of fill-finish work, which involves filling and ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.